LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

The inclusion of monoclonal antibodies targeting immune checkpoints such PD-1/PD-L1 or CTLA-4 has revolutionized the landscape of anti-cancer therapy. However, PD-1 and CTLA-4 blockade failed to achieve clinical benefit in CLL, thus attention has been focused on emerging checkpoints in this malignan...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers Vol. 13; no. 9; p. 2112
Main Authors:	Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, González-Rodríguez, Ana P, Payer, Ángel R, González-García, Esther, López-Soto, Alejandro, Gonzalez, Segundo
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 27-04-2021 MDPI
Subjects:	Blocking antibodies CD223 antigen Chronic lymphocytic leukemia Clinical trials Cloning CTLA-4 protein Cytogenetics Cytokines Cytotoxicity Flow cytometry Gene expression Hematology Immune checkpoint Immunoglobulins Immunomodulation Immunosuppression Immunosurveillance Interleukin 2 Leukemia Leukocytes (mononuclear) Lymphatic leukemia Lymphocytes Lymphocytes T Lymphoma Malignancy Monoclonal antibodies Natural killer cells Patients PD-1 protein PD-L1 protein Peripheral blood mononuclear cells Proteins Software Tumors United States > US Spain relatlimab CLL LAG3 chronic lymphocytic leukemia NK cell immune checkpoint immunotherapy ICB immunosurveillance
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!